Evidence of EZH2 dependent and independent mechanisms of tazemetostat treatment emergent resistance in models of diffuse large B cell lymphoma

被引：0
作者：
Campbell, Carly T.
Jasper, Jeff S.
Daigle, Scott R.
Ribich, Scott A.
Keilhack, Heike
Smith, Jesse S.
Ho, Peter T.
Blakemore, Stephen J.
机构：
来源：
CANCER RESEARCH | 2016年 / 76卷
关键词：
D O I：
10.1158/1538-7445.AM2016-312
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
312
引用
收藏
页数：3
相关论文
共 50 条
  • [31] TAZEMETOSTAT Histone-lysine N-methyltransferase EZH2 inhibitor Treatment of solid tumors Treatment of B-cell lymphomas
    Marques, F.
    DRUGS OF THE FUTURE, 2016, 41 (10) : 595 - 599
  • [32] Targeting DOT1L and EZH2 synergizes in breaking the germinal center identity of diffuse large B-cell lymphoma
    Gobel, Camiel
    Niccolai, Rachele
    de Groot, Marnix H. P.
    Jayachandran, Jayashree
    Traets, Joleen
    Kloosterman, Daan J.
    Gregoricchio, Sebastian
    Morris, Ben
    Kreft, Maaike
    Song, Ji-Ying
    Azarang, Leyla
    Kasa, Eirini
    Oskam, Nienke
    de Groot, Daniel
    Hoekman, Liesbeth
    Bleijerveld, Onno B.
    Kersten, Marie Jose
    Aslam, Muhammad A.
    van Leeuwen, Fred
    Jacobs, Heinz
    BLOOD, 2025, 145 (16)
  • [33] Mouse models of diffuse large B cell lymphoma
    Tabatabai, Areya
    Arora, Aastha
    Hoefmann, Svenja
    Jauch, Maximilian
    von Tresckow, Bastian
    Hansen, Julia
    Fluemann, Ruth
    Jachimowicz, Ron D.
    Klein, Sebastian
    Reinhardt, Hans Christian
    Knittel, Gero
    FRONTIERS IN IMMUNOLOGY, 2023, 14
  • [34] EZH2 Overexpression Is Associated With Inferior Overall Survival in Diffuse Large B-Cell Lymphoma of Non-Germinal Center Type
    Singhal, Rashi
    Boyer, Daniel
    Briski, Robert
    Herrman, Nicholas
    Wilcox, Ryan
    Elenitoba-Johnson, Kojo
    Lim, Megan
    Bailey, Nathanael
    LABORATORY INVESTIGATION, 2015, 95 : 378A - 378A
  • [35] Analysis of c-MYC, EZH2, and Ki-67 in Primary Diffuse Large B Cell Lymphoma (DLBCL) of the Gastrointestinal Tract
    Luria, L.
    Nguyen, J.
    Zhou, J.
    Coppola, D.
    Messina, J.
    Zhang, L.
    MODERN PATHOLOGY, 2014, 27 : 359A - 359A
  • [36] EZH2 W113C is a gain-of-function mutation in B-cell lymphoma enabling both PRC2 methyltransferase activation and tazemetostat resistance
    Chu, Liping
    Tan, Dongxia
    Zhu, Meimei
    Qu, Yuxiu
    Ma, Xin
    Song, Bao-Liang
    Qi, Wei
    JOURNAL OF BIOLOGICAL CHEMISTRY, 2023, 299 (04)
  • [37] Regulation of Hox genes by Polycomb group protein EZH2 plays a critical role in diffuse large B-cell lymphoma cells
    Velichutina, Irina
    Melnick, Ari
    BLOOD, 2007, 110 (11) : 467A - 467A
  • [38] PROGNOSTIC IMPACT OF EZH2 EXPRESSION, H3K27 TRIMETHYLATION AND DNA METHYLATION IN DIFFUSE LARGE B CELL LYMPHOMA
    Lin, S.
    Tsai, C.
    Chuang, S.
    Chou, W.
    HAEMATOLOGICA, 2013, 98 : 127 - 127
  • [39] Targeting EZH2 for the treatment of hepatosplenic T-cell lymphoma
    Pikman, Yana
    Conway, Amy Saur
    Robichaud, Amanda L.
    Kitara, Samuel
    Church, Alanna J.
    Kennedy, Alyssa L.
    Silverman, Lewis B.
    Billett, Amy L.
    Weinstock, David M.
    Harris, Marian H.
    Stegmaier, Kimberly
    BLOOD ADVANCES, 2020, 4 (07) : 1265 - 1269
  • [40] EZH2 Upregulation Is Associated with Unfavorable Prognosis in Diffuse Large B-Cell Lymphoma through Potential RUNX3 Downregulation
    Peker, Denise
    Roman-Holba, Samara
    Kwon, Yuri
    Gordetsky, Jennifer
    Mehta, Amitkumar
    Forero, Andres
    Costa, Luciano J.
    Reddy, Vishnu
    Yang, Yang
    Chakravarthi, Balabhadrapatruni V. S. K.
    Varambally, Sooryanarayana
    BLOOD, 2016, 128 (22)
12345